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N-Formyl peptide receptor-like 1 (fPRL1) is a member of the chemoattractant subfamily of G protein-
coupled receptors and plays a key role in inflammation via chemotaxis and the regulation of mediator release
from leukocytes. Activated fPRL1 has recently been shown to induce a complicated pattern of cellular signaling
in vitro, but the details of the regulation and alteration of leukocyte cellular fPRL1 during inflammation in vivo
remain unclear. To clarify the alteration of neutrophil fPRL1 during inflammation in vivo, the immunohisto-
chemical staining of neutrophil fPRL1 in samples from patients with purulent dermatitis was performed. The
in vitro morphological alteration of neutrophil fPRL1 on cellular membranes by stimulation with N-formyl-
methionyl-leucyl-phenylalanine (fMLP) was also examined. Both the cytoplasm and the cellular membranes of
blood neutrophils stained strongly for fPRL1. On the other hand, the cellular membranes of neutrophils in
dermatitis tissue stained strongly for fPRL1 but the cytoplasm stained weakly. The enhancement of neutrophil
fPRL1 on cellular membranes by stimulation with fMLP indicates the exocytosis of neutrophil fPRL1-
containing granules. In conclusion, we for the first time confirmed the alteration of neutrophil fPRL1 in clinical
cases of purulent dermatitis. Cytoplasm that was weakly stained and cellular membranes that were well stained
for fPRL1 were considered to be distinctive features of activated neutrophils in purulent dermatitis tissue.
N-Formyl peptide receptor-like 1 (fPRL1), which mediates
chemotaxis, degranulation, and respiratory burst, is considered
to be a member of the calcium-mobilizing G protein-coupled
family of receptors for bacterial N-formyl peptides in phago-
cyte cells (16, 17, 18, 23). fPRL1 differs from N-formyl peptide
receptor (fPR), with 69% identity at the amino acid level, and
cDNA encoding fPRL1 is reported to be located on human
chromosome 19 (4, 20, 21), but the biological implications of
fPRL1 have remained poorly understood since it was first
reported in 1999. fPRL1 was identified as one of the receptors
to which an acute-phase reactant, acute-phase serum amyloid
A (A-SAA), is bound, and fPRL1 mediates the chemotaxis of
phagocyte cells such as neutrophils and monocytes (24). fPRL1
is also considered to be an agonistic receptor for mitochondrial
proteins of either damaged host cells or invading pathogens.
Therefore, fPRL1 is involved mainly in the host defense
against infective organisms and in the clearance of damaged
cells (17). Moreover, recent studies indicate that fPRL1 plays
an important role in immune responses distinct from that of
fPR: more than fPR, fPRL1 mediates the chemotactic migra-
tion of phagocytic cells and the resultant production of reactive
oxygen species (16, 17, 23).
A-SAA is an ancient acute-phase reactant produced in re-
sponse to trauma, infection, inflammation, and neoplasia (26,
27). A-SAA is synthesized not only in the hepatocytes, but also
in the extrahepatic cells such as endothelial cells, monocytes,
macrophages, vascular smooth muscle cells, and synovial cells
(13, 14). A-SAA is also reported to be present in the skin (27).
A-SAA is a ligand for fPRL1 which mediates the cellular
calcium influx in neutrophils and results in the migration of
neutrophils (2). Recent neutrophil studies in vitro have found
that the mechanism of fPRL1 activation is complicated and that
bacterial lipopolysaccharides (LPS) need to be primed for the
activation of neutrophils through fPRL1 (1, 6, 7). However,
the details of the physiological alteration and regulation of
neutrophil fPRL1 in response to inflammation in vivo remain
unclear. Moreover, the morphological changes in neutrophil
fPRL1 in relation to the inflammatory process in vivo also
remain unclear.
This study was undertaken to determine whether neutrophil
fPRL1 is immunohistochemically altered and whether the ac-
tive feature of neutrophil fPRL1 in patients with bacterial skin
disease could be characterized by immunohistochemical anal-
ysis. To comprehend the morphological changes in neutrophils
in inflammation, the alteration of neutrophil fPRL1 by stimu-
lation with N-formylmethionyl-leucyl-phenylalanine (fMLP)
was analyzed in vitro.
MATERIALS AND METHODS
Samples. We histologically investigated skin specimens from three patients
with purulent dermatitis (two men and one woman, ages 46 to 70 years old); one
suffered from necrotizing fasciitis (case 1, infection with Bacteroides fragilis and
Propionibacterium species), and two suffered from Fournier gangrene (case 2,
Streptococcus agalactiae infection, and case 3, Candida albicans infection). We
also investigated bone marrow specimens, which were clinically and histologically
determined to be normocellular bone marrow, from 10 patients without inflam-
matory diseases. All samples used in this study were obtained under the approval
of the Hospital Ethics Committee of Kochi Medical School Hospital, Kochi
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University, Kochi, Japan, and were also given with the informed consent of
participants.
Reagents. Tris-buffered saline (TBS; 0.05 M, pH 7.6), normal goat serum, goat
anti-rabbit immunoglobulin-peroxidase conjugate, hematoxylin, and 3,3-diamino-
benzidine tetrahydrochloride were purchased from Nichirei Corporation (Tokyo,
Japan). Phosphate-buffered saline (PBS; 1/15 M, pH 7.4), hydrogen peroxide,
sodium azide, formaldehyde, HEPES, and manganese chloride tetrahydrate
were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan).
fMLP, Histopaque 1083, dextran (average molecular weight, 520,000), acid
citrate, and human serum were purchased from Sigma Chemical Co. (St. Louis,
MO). Dimethyl sulfoxide and glutaraldehyde were purchased from Nacalai
Tesque Inc. (Kyoto, Japan). BlockAce was purchased from Snow Brand Co.
(Sapporo, Japan). Precasting polyacrylamide gels and nitrocellulose membrane
were purchased from Bio-Rad Laboratories (Hercules, CA). Goat anti-rabbit
immunoglobulin G-fluorescein conjugate secondary antibody was purchased
from CHEMICON International (Temecula, CA). All reagents were of the
highest grade available. Stock solutions of phorbol myristate acetate were pre-
pared in dimethyl sulfoxide and stored at 20°C until use.
Preparation of anti-fPRL1 antiserum. Anti-fPRL1 antiserum was originally
prepared by the repetitive immunization of rabbits with the synthetic peptide
TVTIPNGDTYC, corresponding to amino acids 166 to 176 of fPRL1 (21), by a
modification of previously described methods (5). The resulting fPRL1 anti-
serum was confirmed to be specific to human fPRL1 by Western blot analysis and
electron microscopy and to be functionally active by the inhibition of migration
of human vascular smooth muscle cells and synovial cells (14, 15).
Immunohistochemical analyses. For immunohistochemical analyses, tissues
were fixed in 20% formaldehyde in PBS for 1 h at room temperature, dehy-
drated, and embedded in paraffin. Four-micrometer-thick sections were cut,
dehydrated, and subsequently used for immunohistochemistry. Briefly, sections
were deparaffinized, hydrated, and incubated for 10 min in 0.3% hydrogen
peroxide diluted in methanol to reduce endogenous peroxidase activity. Immu-
nostaining was performed using an automated immunostainer (OptiMax Plus;
BioGenex, San Ramon, CA). The sections were incubated with 1:500-diluted
primary antibody polyclonal anti-fPRL1 in TBS for 1 h at room temperature.
After rinsing in TBS, the slides were incubated with 10% normal goat serum in
TBS for 15 min to prevent nonspecific binding of the secondary antibody. After
washing twice in TBS, sections were incubated with 1:1,000-diluted goat anti-
rabbit immunoglobulin G-peroxidase conjugate for 30 min, followed by subse-
quent labeling with 3,3-diaminobenzidine tetrahydrochloride for 40 s at room
temperature. Sections were counterstained with hematoxylin. The specificity of
the immunohistochemical procedure was checked using negative and positive
controls.
Quantification of fPRL1 staining in neutrophils. The immunostaining of neu-
trophils for fPRL1 was observed at high power (magnification, 1,000) with a
standard light microscope. With pictures of immunostained samples imported
through the video camera, the intensity of fPRL1 immunostaining in neutrophils
was quantitatively estimated using the NIH Image analysis program (National
Institutes of Health, Bethesda, MD; http://rsb.info.nih.gov/nih-image/). In brief,
the pictures of immunostained samples were automatically converted to mono-
chrome images and then the spot intensities in neutrophil cytoplasm were arbi-
trarily graded from 0 for white to 100 for black. The intensities of the neutrophil
staining were represented by the mean of the values for three randomly selected
spots within the neutrophil cytoplasm. The intensity of neutrophil staining in the
visual field was presented as the mean  the standard deviation (SD) of the
intensity values for 10 randomly selected neutrophils.
Isolation of human neutrophils. Neutrophils were purified from whole-blood
samples (provided by Y.K.) as previously described (11). Briefly, whole-blood
samples were intravenously obtained and collected in plastic syringes, followed
by the separation of leukocytes from erythrocytes by sedimentation in 6% dex-
tran with acid citrate (1 mg/10 ml of blood) as an anticoagulant. The purification
of isolated human neutrophils was performed with Histopaque 1083 by centrif-
ugation at 110  g for 10 min at 4°C, followed by the hypotonic lysis of residual
erythrocytes with cold distilled water for 30 s. Neutrophils were maintained in
cold HEPES buffer (135 mM NaCl, 5 mM KCl, 1 mM CaCl2, 5 mM glucose, and
20 mM HEPES, pH 7.4) until use. Neutrophil samples comprising 95% viable
cells were suspended in HEPES buffer with a purity of 98% and assessed by
light microscopy.
Exocytosis of fPRL1 in vitro by stimulation. fMLP has previously been iden-
tified as a potent leukocyte chemoattractant, and previous studies have demon-
strated that fMLP binds to fPRL1 and induces intracellular signaling via fPRL1
(16, 17). Therefore, neutrophils were stimulated by treatment with fMLP. Neu-
trophils (106 cells/ml) suspended in HEPES buffer were incubated with 106 M
fMLP for 15 min at 37°C. Following stimulation, neutrophils were washed three
times in cold HEPES buffer. Next, the cells were incubated with 1:500 anti-
fPRL1 serum or preimmune serum in PBS for 15 min at 37°C. After being
washed three times in cold HEPES buffer, neutrophils were incubated with
1:1,000 goat anti-rabbit immunoglobulin G-peroxidase conjugate in PBS for 15
FIG. 1. Immunohistochemical staining of fPRL-1 in neutrophils (A) and
expression of fPRL1 staining intensities in the neutrophil cytoplasm as mea-
sured in digitally remastered images (B) (case 1). In panel A, immunostaining
pictures show that neutrophil fPRL1 was strongly stained in the blood (a) and
weakly stained in the central area of the dermatitis tissue (d). In panel B, the
intensities of fPRL1 staining in the cytoplasm of neutrophils from the indi-
cated areas were expressed in arbitrary units (EU) and plotted. The fPRL1
intensities decreased significantly in succession (one-way analysis of variance)
from that in the blood (area a, 74.3  2.7 arbitrary units) to those in the
peripheral margin (area b, 54.3 2.6 arbitrary units), the intermediate area
(area c, 48.4  5.6 arbitrary units), and the central area (area d, 40.1  3.1
arbitrary units) of the dermatitis tissue. Asterisks indicate significant (P 
0.05) differences between the groups. Scale bars, 50 m.
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min at 37°C. Neutrophils were washed three times in cold HEPES buffer and
fixed with 2% glutaraldehyde in HEPES buffer at 4°C for 30 min. After centrif-
ugation at 110  g for 10 min at 4°C, the cells were suspended in a small volume
of HEPES buffer and then layered onto round coverslips (12 mm in diameter).
Flow cytometry. The reactive changes in fPRL1 on neutrophil membranes
were examined following fMLP stimulation by flow cytometric analysis using a
BD FACSCalibur flow cytometer (Becton Dickinson, San Diego, CA). Neutro-
phils (106 cells/ml) suspended in HEPES buffer were incubated with fMLP (106
M) for 5, 10, and 15 min at 37°C. Neutrophils were collected at 4°C and fixed with
1% formaldehyde and 0.05% glutaraldehyde and washed three times in PBS.
Then the cells were incubated with 1:500 anti-fPRL1 serum in PBS for 2 h at
room temperature. After the cells were washed three times with rinse buffer
containing 2.5% human serum, 0.1% sodium azide, and 10% BlockAce in PBS,
the cell suspensions were incubated with goat anti-rabbit immunoglobulin G-
fluorescein conjugate secondary antibody for 30 min at room temperature. Neu-
trophils were gated according to the height of their fluorescence intensity. The
intensity of fluorescence for specific antibodies was corrected for nonspecific
fluorescence by subtracting the fluorescence for the secondary antibody alone.
The experiments were repeated three times.
Fluorescence microscopy. The exocytosis of neutrophils was visualized using a
fluorescence microscope (Axiovert S100TV; Zeiss, Jena, Germany) after the
immunofluorescent staining of neutrophils. Briefly, following stimulation, 1 
105 to 5  105 neutrophils were washed twice with rinse buffer. After washing,
cell suspensions were incubated with 1:500 rabbit anti-fPRL1 serum or the
preimmune serum prepared before the first immunization for 30 min at 4°C.
After the cells were washed three times with rinse buffer, the cell suspensions
were incubated with 1:1,000 goat anti-rabbit immunoglobulin G-peroxidase con-
jugate in rinse buffer for 30 min at 4°C. After three washes with rinse buffer, the
cells were suspended in a small volume of rinse buffer and mounted onto a glass
slide, and then fluorescence microscopy was performed.
Statistical analysis. Data are presented as means  SD. A comparison of
variables between two groups or among three or more groups was performed
using Mann-Whitney’s U test or one-way analysis of variance, respectively. Re-
sults were considered significant when the P value was less than 0.05.
RESULTS
Intensity of fPRL1 staining in neutrophils in tissues. As the
intensity of the immunohistochemical staining of the cytoplas-
mic fPRL1-invaded neutrophils varied from sample type to
sample type, the fPRL1 staining intensity in the neutrophil
cytoplasm as measured in photographs was expressed numer-
ically. The intensity of fPRL1 staining in the cytoplasm of the
neutrophils in blood was high, but that of the neutrophils in
dermatitis tissue was low (Fig. 1A). In the dermal tissue, the
neutrophils located in the central area (Fig. 1A, area d) of the
inflammation stained less intensely for fPRL1 than those in
the peripheral margin (Fig. 1A, area b). Values expressing the
staining intensities in neutrophil cytoplasm in digitally remas-
tered images are shown in Fig. 1B. Values for fPRL1 staining
intensity in blood (74.3  2.7 arbitrary units) (Fig. 1A, area a)
were significantly higher than those for staining intensity in the
dermal tissue. Values for fPRL1 staining in the peripheral
margin of the dermal tissue (54.3  2.6 arbitrary units) (Fig.
1A, area b) were significantly higher than those for staining in
the intermediate area (48.4  5.6 arbitrary units) (Fig. 1A,
area c) and in the central area (40.1 3.1 arbitrary units) (Fig.
1A, area d). fPRL1 values for the intermediate area (between
the central area and the peripheral margin) were intermediate,
and the distribution pattern in Fig. 1A, area c, shows a mix of
patterns from area b and area d. As shown in Fig. 2, the
intensity of the fPRL1 staining in neutrophil cytoplasm in case
1 specimens was identical to the intensities in samples from
case 2 and case 3. We also investigated the intensity of the
staining of neutrophils in bone marrow (Fig. 3), and bone
marrow neutrophil fPRL1 (intensity, 66.4 6.4 arbitrary units)
stained as that in blood. The fPRL1 staining intensity in the
cytoplasm of the bone marrow neutrophils was statistically
different from that of neutrophils in the blood (case 1, 74.3 
2.7 arbitrary units; case 2, 70.6  2.6 arbitrary units; and case
3, 74.2  2.9 arbitrary units).
FIG. 2. The intensities of immunohistochemical fPRL1 staining in the neutrophil cytoplasm in dermatitis tissues from case 2 and 3 patients were
expressed in arbitrary units (EU) and plotted. The fPRL1 staining intensities in the dermatitis tissues were significantly lower than those in the
blood (in both cases 2 and 3). Values of fPRL1 staining intensity were as follows: case 2, 70.6  2.6 (area a, corresponding to area a in Fig. 1A),
54.1  2.6 (area b), and 40.2  3.0 (area c); case 3, 74.2  2.9 (area a), 57.5  2.4 (area b), and 41.7  3.7 (area c). Asterisks indicate significant
(P  0.05) differences between the groups.
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We further investigated the morphological changes in neu-
trophils in relation to fPRL1 staining. As shown in Fig. 4 (case
1), we found that the fPRL1 staining intensity in the neutrophil
cytoplasm decreased as neutrophils from the blood infiltrated
the inflamed tissue. In the dermatitis tissue, the neutrophil
cellular membranes stained strongly for fPRL1, but the cyto-
plasm was less stained. These data suggest that the shift of
neutrophil fPRL1 from the cytoplasm to the cellular mem-
brane during inflammation is due to exocytosis. There were no
morphological changes in neutrophils indicative of apoptosis,
which is characterized by shrinkage, the compaction of chro-
matin, or the loss of the multilobed shape of the nucleus.
Alteration of cellular neutrophil fPRL1 in vitro by fMLP
stimulation. The alteration of neutrophil fRPL1 present on
cellular membranes by fMLP stimulation for up to 15 min was
monitored using flow cytometry (Fig. 5). Upon stimulation
with 1 M fMPL, M1 area values for neutrophil fPRL1, ex-
pressed as percentages of the area under the curve, increased
throughout the time course (1.6%  0.03% at time 0, 7.1% 
0.39% at 5 min, 10.4% 1.28% at 10 min, and 20.1% 3.19%
at 15 min).
We investigated microscopically the morphological changes
in neutrophil fPRL1 in vitro after incubating the neutrophils
with fMLP. As shown in Fig. 6, the neutrophils shone brightly
after fMLP stimulation, suggesting that the levels of neutrophil
fPRL1 on the cellular membranes increased after fMLP stim-
ulation.
DISCUSSION
Neutrophils are considered to be part of the first line of
defense against bacterial infections, and the activation of neu-
trophils is induced by chemotactic receptors of fPR and fPRL1.
fPRL1 is expressed not only in the neutrophils, but also in a
variety of cells including phagocytes, epithelial cells, T lympho-
cytes, vascular endothelial cells, vascular smooth muscle cells,
and synovial cells (14, 15, 16, 17, 18, 23), all of which are
considered to be capable of participating in inflammation. The
mobilization of neutrophil fPRL1 to the cellular membrane by
LPS and proinflammatory mediator stimuli in vitro has been
reported previously (1, 6, 7), but there is no in vivo study of
neutrophil fPRL1. This is the first clinical report describing the
pathological changes in human neutrophil fPRL1 in the in-
flamed tissue in vivo. We found that (i) the fPRL1 staining
intensity in neutrophil cytoplasm in the inflamed tissue was
lower than that in the blood and that (ii) the fPRL1 staining
intensity on neutrophil cellular membranes increased in con-
trast to the decrease of intensity in the neutrophil cytoplasm.
This fact is conceivably explained by the exocytosis of neutro-
phil fPRL1 (8).
FIG. 3. Immunohistochemical staining of bone marrow with anti-fPRL1 (A) and intensities of fPRL1 staining in neutrophil cytoplasm (B). The
segmented neutrophils in the bone marrow and blood of 10 patients with normocellular bone marrow were stained. The mean intensity of fPRL1
staining in the neutrophil cytoplasm in bone marrow was 66.4  6.4 arbitrary units (EU). Scale bar, 50 m.
FIG. 4. Morphological differences in neutrophil fPRL1 staining patterns in blood (A) and dermatitis tissue (B) (case 1) were investigated. The
entire intracellular cytoplasm area of neutrophils in blood stained well, whereas neutrophils in the dermatitis tissue exhibited cytoplasm that was
less stained but cellular membranes that were strongly stained (arrows). Scale bars, 50 m.
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In dermatitis tissue, the level of cytoplasmic neutrophil
fPRL1 was clearly different from that in the blood, which was
characterized by decreased fPRL1 staining intensity in neutro-
phil cytoplasm and increased fPRL1 staining intensity on neu-
trophil membranes. We also found that neutrophil cytoplasm
in the dermatitis tissue was less stained by Naphtol AS-D
chloroacetate esterase than that in the blood (data not shown).
It has been reported previously that the alkaline phosphatase
in neutrophils is located intracellularly while neutrophils are
unstimulated but moves to the cellular surface after stimula-
tion (11). The distinctive staining features of neutrophil fPRL1
in the dermatitis tissue indicate that fPRL1 acts like alkaline
FIG. 5. The alteration of fPRL1 on neutrophil membranes throughout the time course of fMLP stimulation was investigated using flow
cytometry. Neutrophils (106 cells/ml) were incubated with 1 M fMLP for 5, 10, and 15 min at 37°C, followed by flow cytometric analysis. The levels
of membranous fPRL1-bearing neutrophils, expressed as percentages of the area under the curve (M1), markedly increased after fMLP stimulation
(1.6%  0.03% at time 0, 7.1%  0.39% at 5 min, 10.4%  1.28% at 10 min, and 20.1%  3.19% at 15 min). The fPRL1 fluorescence intensity
is expressed in arbitrary units. Representative patterns of neutrophil membranous fPRL1 are shown. Data are means  SD of results from three
independent experiments yielding similar results. SSC-H, side scatter-height; FSC-H, forward scatter-height.
FIG. 6. The change in fPRL1 on neutrophil surfaces after 15 min of stimulation with 106 M fMLP is shown. Neutrophils were visualized by
fluorescence microscopy. (a) Unstimulated neutrophils stained with anti-fPRL1 antiserum; (b) fMLP-stimulated neutrophils stained with preim-
mune serum; and (c) fMLP-stimulated neutrophils stained with anti-fPRL1 antiserum. fMLP markedly induced fPRL1 presentation on the cellular
membrane (c), suggesting the exocytosis of fPRL1-containing granules.
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phosphatase. These facts indicated that the activated neutro-
phils infiltrate the inflamed tissue in proportion to the increase
in the grade of inflammation (Fig. 1A, areas c and d). This
pathognomonic feature of neutrophil fPRL1 was confirmed by
fMLP stimulation in vitro (Fig. 5 and 6). The life span of
neutrophils in circulation is reported to be 6 to 8 h (29).
However, it is prolonged when the neutrophils are incubated
with proinflammatory cytokines and mediators (22). Neutro-
phil fPRL1, depending on the ligands, is also reported to play
an important role in activating and inactivating inflammation
(16, 17, 18, 23). Therefore, whether these morphological char-
acteristics of neutrophils are related to the neutrophil function
(phagocytosis) or to the near-future outcome for the neutro-
phils (apoptosis) is worthy of consideration.
The upregulation of fPRL1 on neutrophil membranes,
regarded as the activation of neutrophils, is induced by
preincubation with bacterial LPS and/or cytokines but is
hardly induced without this priming condition (1, 6, 7).
There is no previous report of neutrophil activation in the
bloodstream during inflammation. Contrary to our expecta-
tions, we found a significant difference in fRPL1 staining in-
tensities in neutrophil cytoplasm, with higher intensities in
blood and lower intensities in bone marrow. This pattern is
hard to understand in theory, because neutrophils activated in
the bloodstream should have already been stimulated before
infiltrating the inflamed tissue in patients with purulent der-
matitis. Our finding cannot be explained definitively, but we
can raise possible reasons as follows. First, the level of neutro-
phil fPRL1 in bone marrow is possibly underestimated. The
maturation of bone marrow neutrophils proceeds heteroge-
neously, and immature but not mature neutrophils in bone
marrow are reported to have secretory vesicles poor in fPRL1
(8). Second, the level of neutrophil fPRL1 in the bloodstream
may be increased by some mechanisms induced by inflamma-
tion, including the transcriptional upregulation of the fPRL1
gene. We do not know whether this discrepancy has any sig-
nificance, because we did not directly investigate the neutro-
phil fPRL1 staining intensity in bone marrow from patients
with purulent dermatitis (cases 1 to 3). Moreover, the precise
mechanism related to the upregulation of cytoplasmic neutro-
phil fPRL1 is yet to be determined, but there is a possibility
that the production of neutrophil fPRL1 may have been up-
regulated by proinflammatory cytokines.
Aside from fMLP, T21/DP107, and the W peptide (16, 17,
23), several endogenous agonists and antagonists involved in
the inflammatory process have been reported to interact with
fRPL1. Lipoxin A4, a metabolite of prostaglandins, has been
reported to be a potent inhibitor of acute inflammation
through the suppression of chemokine production by fPRL1-
positive cells (9, 25). A-SAA, another endogenous ligand, has
also been reported to promote or inhibit the migration of
neutrophils through fPRL1 (3, 10) and to inhibit the oxidative
burst response of neutrophils stimulated by fMLP (19). How-
ever, these previous results are all different and depend on the
condition of the cells, the culture conditions, or the type of
experiment. A-SAA is chemotactic for the migration of human
aortic smooth muscle cells and synovial fibroblasts, and the
A-SAA-induced migration of human aortic smooth muscle
cells and synovial fibroblasts is inhibited by anti-fPRL1 (14,
15). In addition to the production of proinflammatory cyto-
kines after stimulation with bacterial LPS, A-SAA locally syn-
thesized in the skin (27) and additionally produced by the
infiltrated monocytes and macrophages (28) may be implicated
in neutrophil migration in dermatitis.
The chemotactic migration of neutrophils and vascular
smooth muscle cells via fPRL1 is mediated by the activation of
protein kinase C, phosphatidylinositol 3-kinase, Ras of small G
protein, and p38–mitogen-activated protein kinase (12, 18).
Although the major pathway of fPRL1 signal transduction and
the relationships of fPRL1 signaling to the neutrophil func-
tions including the exocytosis of granules are not known, the
tertiary gelatinase granules of the neutrophils are reported to
be the potential stores of fPRL1 (1, 6). These data indicate a
clinical linkage between gelatinase and fPRL1 in the inflam-
matory process.
In conclusion, neutrophil fPRL1 staining of the purulent
dermatitis tissue revealed lower fPRL1 staining intensity in the
cytoplasm and higher intensity on the cellular membranes of
neutrophils, indicating the exocytosis of fPRL1 during neutro-
phil invasion.
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